Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
Part of paid clinical trials in Milwaukee, Wisconsin.
- Sponsor
- Medical College of Wisconsin
- Study ID
- NCT07185204
- Status
- Recruiting
Conditions
- Postpartum Preeclampsia
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Early detection and management of postpartum preeclampsia bundle — OTHERRemote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
Study Details
The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.
Key Dates
- First listed
- Sep 22, 2025
- Start date
- Mar 3, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: High-risk InterventionParticipants with high-risk sFlt-1/PlGF ratio randomized to early detection and management of postpartum preeclampsia with remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
- No Intervention: High-Risk ControlParticipants with high-risk sFlt-1/PlGF ratio randomized to standard postpartum care.
- No Intervention: Low-risk ControlParticipants with low-risk sFlt-1/PlGF ratio will not be randomized, but will remain enrolled to assess the exploratory outcome of biomarker predictive ability.
Primary Outcome Measure
Study feasibility [ Time Frame: 1 year ]
Central Contacts
- Alyssa Hernandez, DO4148055285
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Milwaukee, WI
By research site
Related Studies
- Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled TrialPHASE4 · Recruiting · Nebraska Methodist Health System · Omaha, Nebraska
- Wearables to Define Postpartum Blood Pressure Trajectories and Facilitate Evidence-based Monitoring GuidelinesEnrolling By Invitation · University of California, San Diego · La Jolla, California
- Rhode Island - Statewide Postpartum Hypertension Remote SurveillanceRecruiting · Women and Infants Hospital of Rhode Island · Newport, Rhode Island
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension StudyRecruiting · The Cleveland Clinic · Cleveland, Ohio